Twenty-two patients with recurrent malignant glioma (13 of whom had GBM) were treated with intranodal injections of αDC1 loaded with synthetic peptides for EphA2, IL13Rα2, YKL-40, and gp100 HLA-A2 restricted epitopes in this phase I/II study. This evidence concerns the gene PMEL and glioblastoma.